← Back to headlines
Spyre Therapeutics Prices Upsized $403M Stock Offering
Spyre Therapeutics has priced an upsized stock deal, raising $403 million in gross proceeds, which significantly exceeds its initial target of $300 million.
15 Apr, 04:26 — 15 Apr, 04:26
Sources
Showing 1 of 1 sources
